Price movement over the last 24 hours
Archer Aviation Inc vs Johnson & Johnson — how do they compare? Archer Aviation Inc trades at $4.84 (market cap $3.76B), while Johnson & Johnson trades at $266.14 (market cap $643.30B). The key difference: Johnson & Johnson is far larger — about 171.1× Archer Aviation Inc's market cap, and Johnson & Johnson pays a 2.01% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | JNJ | |
|---|---|---|
Market Cap | $3.76B | $643.30B |
Sector | Industrials | Health |
52-Week High | $13.64 | $267.24 |
52-Week Low | $4.68 | $155.17 |
Enterprise Value | $2.11B | $676.24B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →